Quarterly ResultMay 6, 2026, 04:15 PM
Tarsus Q1 XDEMVY Sales $145.4M, +85% YoY; Net Loss $7.0M
AI Summary
Tarsus Pharmaceuticals reported strong first quarter 2026 financial results, driven by significant growth in XDEMVY net product sales, which increased over 85% year-over-year to $145.4 million. The company reaffirmed its full-year 2026 guidance for XDEMVY sales at $670-700 million and reduced its net loss to $7.0 million. Tarsus also highlighted progress in its pipeline, including the initiation of a Phase 2 trial for TP-05 for Lyme disease prevention and regulatory approval for TP-03 (XDEMVY) in China.
Key Highlights
- XDEMVY net product sales reached $145.4 million, an increase of over 85% year-over-year.
- Reaffirmed full-year 2026 guidance for XDEMVY net product sales of $670-700 million.
- Total revenues for Q1 2026 were $162.1 million, up from $78.3 million in Q1 2025.
- Net loss improved to $7.0 million, compared to $25.1 million in Q1 2025.
- License fees and collaboration revenue were $16.7 million, including a $15.0 million milestone payment.
- Research and development expenses increased to $22.4 million from $14.4 million year-over-year.
- Selling, general and administrative expenses rose to $136.4 million from $85.0 million year-over-year.
- Cash, cash equivalents, and marketable securities stood at $388.7 million as of March 31, 2026.